Recently, IDH1/IDH2 glioma diagnoses could be performed intraoperatively with biopsy tissue samples using the oncometabolite 2-hydroxyglutarate (2-HG)4, which alters epigenetic regulation and contributes to tumor progression. This evidence concerns the gene IDH1 and central nervous system cancer.